Tsiodras et al. BMC Cancer 2010, 10:53 http://www.biomedcentral.com/1471-2407/10/53 with the hybrid capture 2 assay are reproducible. J Clin Microbiol 2002, 40(3):1088-1090. 17. Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, et al: Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998, 36(11):3248-3254. 18. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, et al: Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004, 42(6):2470-2475. 19. Yamazaki H, Sasagawa T, Basha W, Segawa T, Inoue M: Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer 2001, 94(2):222-227. 20. Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, Fukuchi T, Kubushiro K, Tsukazaki K, Nozawa S: Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003, 88(12):1883-1888. 21. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P: HPV testing in primary screening of older women. Br J Cancer 1999, 81(3):554-558. 22. Meijer CJ, Brule van den AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM: Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 1992, , 119: 271-281. 23. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ: Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995, 172(3):946-954. 24. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, Linden van der HC, Voorhorst FJ, Kenemans P, Meijer CJ: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354(9172):20-25. 25. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, et al: Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999, 281(17):1605-1610. 26. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Gabriel R, Quereux C, Birembaut P: Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999, 80(9):1306-1311. 27. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Arveux P, Seilles E, Mougin C: Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 1999, 8(3):157-164. 28. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J: Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006, 24(Suppl 3):S90-97. 29. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC: Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000, 92(10):818-825. 30. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al: Persistence of type- specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994, 169(2):235-240. 31. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003, 95(1):46-52. 32. Kjaer SK, Brule van den AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325(7364):572. 33. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P: Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001, 84(12):1616-1623. Page 8 of 8 34. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA: Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005, 191(5):731-738. 35. Richart RM, Masood S, Syrjanen KJ, Vassilakos P, Kaufman RH, Meisels A, Olszewski WT, Sakamoto A, Stoler MH, Vooijs GP, et al: Human papillomavirus. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol 1998, 42(1):50-58. 36. Lorincz AT, Richart RM: Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003, 127(8):959-968. 37. Kaufman RH, Adam E, Icenogle J, Reeves WC: Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness. Am J Obstet Gynecol 1997, 177(4):930-936. 38. Nuovo GJ: Detection of human papillomavirus in Papanicolaou smears: correlation with pathologic findings and clinical outcome. Diagn Mol Pathol 1998, 7(3):158-163. 39. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87(18):1365-1371. 40. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P: The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995, 61(3):306-311. 41. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350. Pre-publication history The pre-publication history for this paper can be accessed here:http://www. biomedcentral.com/1471-2407/10/53/prepub doi:10.1186/1471-2407-10-53 Cite this article as: Tsiodras et al.: Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer 2010 10:53. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit